ABSTRACT
INTRODUCTION South Asian (SA) and East Asian (EA) older adults represent the fastest growing group of Americans at risk for dementia, but their participation in aging and dementia research has been limited. While recruiting healthy SA older adults into a brain health study, we encountered unexpected hesitancy towards structural brain MRI analysis along with some stigmatizing attitudes related to internal locus of control (LoC) for future dementia risks. We hypothesized that support for MRI-related research was influenced by these attitudes as well as one’s own MRI experience, perceived MRI safety, and concerns for one’s own risks for future dementia/stroke.
METHODS We developed a brief cross-sectional survey to assess older adults’ MRI experiences and perceptions, desire to learn of six incidental findings of increasing health implications, and attitudes related to dementia as well as research participation. We recruited a convenience sample of 256 respondents (74% reporting as 50+) from the New Jersey/New York City area to complete the survey, and modeled the proportional odds (P.O.) for pro-research attitudes.
RESULTS 77 SA and 84 EA respondents were analyzed with 95 non-Asian adults. White (P.O.=2.54, p=0.013) and EA (P.O.=2.14, p=0.019) respondents were both more likely than SA respondents to endorse healthy volunteers’ participation in research, and the difference between White and SA respondents was mediated by the latter’s greater internal LoC for dementia risks. EA respondents had more worries for future dementia/stroke than SA respondents (p=0.006), but still shared SA respondents’ low desire to learn of incidental MRI findings.
DISCUSSION SA and EA older adults had different attitudes towards future dementia/stroke risks, but shared a low desire to learn of incidental MRI findings. A culturally-appropriate protocol to disclose incidental MRI findings may improve SA and EA participation in brain health research.
Color printing Please have figure one and two be in color; figure three is in black and white
Competing Interest Statement
William T Hu has patents on CSF-based diagnosis of FTLD-TDP, prognosis of mild cognitive impairment due to Alzheimer's disease, and prognosis of spinal muscular atrophy treatment; has consulted for Biogen, Fujirebio Diagnostics, and Roche
Funding Statement
This work has been supported by NIH R24 AG063729, NIH P30 AG059304, Rutgers Center for Advanced Human Brain Imaging Research, and Rutgers Biomedical and Health Sciences
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board of Advarra gave ethical approval for this work (study was considered exempt human subject research)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Conflicts: WTH has patents on CSF-based diagnosis of FTLD-TDP, prognosis of mild cognitive impairment due to Alzheimer’s disease, and prognosis of spinal muscular atrophy treatment; has consulted for Biogen, Fujirebio Diagnostics, and Roche.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Abbreviations
- (EA)
- East Asian
- (SA)
- South Asian
- (LoC)
- Locus of Control
- (PCA)
- Principal Component Analysis
- (PC)
- Principal Component
